发现口服可生物利用的ALK PROTACs,基于对抗ALK阳性癌症的利尼布
Haoxuan Zhou1, Mingxing Hu1, Hui Jie2
1Department of Nuclear Medicine and Clinical Nuclear Medicine Research Lab, West China Hospital, Sichuan University, Chengdu, 610041, China.
European journal of medicinal chemistry
|September 17, 2024
概括
新的蛋白质溶解向嵌合体 (PROTAC) 分子向形淋巴瘤激酶 (ALK) 融合蛋白提供了一种有前途的策略,以克服ALK驱动癌症的耐药性. PROTAC 4B显示出强大而持久的ALK降解,在体外和体内表现出显著的抗增殖活性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 无细胞淋巴瘤激酶 (ALK) 融合基因是各种人类癌症的关键驱动因素.
- 对ALK抑制剂的获得性耐药性是一个重大的临床挑战.
- 蛋白质溶解向嵌合体 (PROTAC) 技术为克服药物耐药性提供了一种新的治疗方法.
研究的目的:
- 开发和优化新的ALK向PROTACs,以克服获得的耐药性.
- 为了研究ALK PROTACs的结构-活性关系.
- 在临床前模型中评估一个主要的PROTAC化合物 (4B) 的疗效.
主要方法:
- 设计和合成一系列ALK PROTACs通过通过优化链接器将Ceritinib与thalidomide结合.
- 评估PROTACs诱导三元复合体形成和向蛋白质降解的能力.
- 在实验室中评估ALK阳性癌细胞中的抗增殖活性和下游途径抑制.
- 使用异种移植模型的体内疗效研究和对抗耐药突变的活性评估.
主要成果:
- 在PROTAC中微妙的结构修改显著影响了他们的活动,突出了PROTAC构造的重要性.
- 口服生物可用的PROTAC 4B在卡帕斯299细胞中显示出ALK融合蛋白的强大和持续的降解.
- 在实验室中,PROTAC 4B表现出与Ceritinib相似的抗增殖活性,并且对G1202R突变具有更高的活性.
- 在体内,PROTAC 4B在异种移植模型中显著抑制瘤生长.
结论:
- 优化的ALK PROTACs,特别是4B,在降解ALK融合蛋白和克服抗药性方面是有效的.
- PROTAC 4B在ALK驱动的恶性瘤中显示出有前途的治疗潜力,包括具有抗性突变的恶性瘤.
- 这项研究强调了PROTAC构成在实现强大的标降解和治疗疗效方面发挥的关键作用.
更多相关视频
10:44Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
13.1K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
